Search

Displaying results 2561 - 2570 of 7503 in total
  1. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [L51194] The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases. … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.

  2. Drug

    Dithiazanine

    go.drugbank.com/drugs/DB11516
    ApprovedVet approvedWithdrawn

    Dithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032] … However, its use is severely limited due to its toxicity. Dithiazanine iodide was associated with eight fatal cases of severe acidosis and shock between 1961 and 1964.

  3. Drug

    Albumin human

    go.drugbank.com/drugs/DB00062
    ApprovedInvestigational

    This is a biosimilar drug to existing human serum albumin and was approved for a biological license at both 5% and 25% concentrations by the FDA on June 21, 2018 [L3101]. … It binds to water, cations (such as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals (including barbiturates).

  4. Drug

    Magnesium silicate

    go.drugbank.com/drugs/DB13249
    ApprovedWithdrawn

    [L2603] Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.[L2605]

  5. Drug

    Diloxanide

    go.drugbank.com/drugs/DB08792
    Experimental

    Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.

  6. Drug

    Methylprednisolone

    go.drugbank.com/drugs/DB00959
    ApprovedInvestigationalVet approved

    [A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.

    Mixtures: Neo-medrol, NEO-MEDROL ACNE LOTION
  7. Drug

    Iproniazid

    go.drugbank.com/drugs/DB04818
    ApprovedWithdrawn

    Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.

    Categories: Monoamine Oxidase Inhibitors, Non-Selective, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Dacarbazine

    go.drugbank.com/drugs/DB00851
    ApprovedInvestigational

    An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

  9. Drug

    Ibrexafungerp

    go.drugbank.com/drugs/DB12471
    Approved

    [A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity. … [A235384,L34349] It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole antifungals.

  10. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients.